Resveratrol--a prostate cancer chemopreventive agent?
The incidence of prostate cancer in Western countries continues to rise. Whilst opinion remains divided on the best treatment for localized disease, intervention for metastatic, hormone-independent cancer remains extremely limited. The concept of chemoprevention is gaining popularity as an effective means of reducing the burden of prostate cancer on the population, and many compounds with putative chemopreventive activity are currently under investigation. Resveratrol is a plant-derived polyphenolic compound which has a wide spectrum of biological activity. It has anti-oxidant and anti-inflammatory properties, and may induce apoptosis as well as modulate the function of the androgen receptor in prostate cancer cell lines. Further studies to evaluate the use of this compound as a chemopreventive agent in prostate cancer are warranted.
Ratan
Hari L
HL
Division of Urology, University of Leicester, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK.
Steward
Will P
WP
Gescher
Andreas J
AJ
Mellon
J Kilian
JK
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D018890:Chemoprevention; D006801:Humans; D009369:Neoplasms / Q000517:prevention & control*; D011944:Receptors, Androgen / Q000378:metabolism; D000077185:Resveratrol; D013267:Stilbenes / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D000972:Antineoplastic Agents, Phytogenic; D011944:Receptors, Androgen; D013267:Stilbenes; D000077185:Resveratrol